Clinical Trials Directory

Trials / Completed

CompletedNCT06757751

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus.

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
116 (actual)
Sponsor
Fundacin Biomedica Galicia Sur · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Since Galician virgin olive oils have a high content of bioactive phenolic compounds and these are attributed to a large part of the healthy properties of the Mediterranean Diet, our starting hypothesis is that these olive oils could attenuate insulin resistance, improving glycemic control in terms of fasting plasma glucose and/or glycated hemoglobin and insulin sensitivity.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTEVOO diet supplementFor 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).

Timeline

Start date
2021-04-30
Primary completion
2022-07-22
Completion
2022-09-30
First posted
2025-01-03
Last updated
2025-01-06

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06757751. Inclusion in this directory is not an endorsement.

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus. (NCT06757751) · Clinical Trials Directory